Group 1 - The company Tianjin Tasly Pharmaceutical Group Co., Ltd. has been recognized for its outstanding performance in quality operations, innovative breakthroughs, and social contributions [1] - The company has been shortlisted for the "2024-2025 Most Respected Enterprises" by Economic Observer, based on preliminary evaluations by the organizing committee [1]

Group 1 - The core point of the article is that Tian Shi Li has received a drug registration certificate for its product "Wen Jing Tang Granules" from the National Medical Products Administration [1] - Tian Shi Li's revenue composition for the year 2024 is as follows: Traditional Chinese medicine accounts for 70.89%, chemical preparations for 15.38%, pharmaceutical commerce for 10.53%, biological drugs for 2.25%, and chemical raw materials for 0.61% [1] - As of the report, Tian Shi Li's market capitalization stands at 23.8 billion yuan [1]

证券代码：600535 证券简称：天士力 编号：临 2025-068 号 天士力医药集团股份有限公司 关于公司药品温经汤颗粒获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，天士力医药集团股份有限公司（以下简称"公司"）收到国家药品监 督管理局颁发的关于温经汤颗粒（以下简称"该药品"）的《药品注册证书》， 现将相关情况公告如下： 一、药品的基本情况 药品名称：温经汤颗粒 剂型：颗粒剂 规格：每袋相当于饮片 10g 注册分类：中药 3.1 类 证书编号：2025S03004 药品批准文号：国药准字 C20250013 上市许可持有人：天士力医药集团股份有限公司 生产企业：天士力医药集团股份有限公司 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本品 符合药品注册的有关要求，批准本品上市，发给药品注册证书。 二、药品的相关信息 温经汤颗粒处方来源于宋•陈自明《妇人大全良方》，并已列入国家中医药 管理局发布的《古代经典名方目录（第一批）》，由肉桂、酒当归、川芎、醋莪 术、牡丹皮、酒牛 ...

Core Viewpoint - Tianshili (600535.SH) has received a drug registration certificate from the National Medical Products Administration for its product, Wengjing Decoction Granules, which enhances blood circulation and alleviates pain, particularly for women experiencing menstrual irregularities and abdominal pain [1] Summary by Categories Product Development - The company has invested a total of 10.72 million RMB in the research and development of Wengjing Decoction Granules [1] Market Positioning - The approval of Wengjing Decoction Granules enriches the company's portfolio in traditional Chinese medicine products [1]

Core Viewpoint - The company has received a drug registration certificate from the National Medical Products Administration for its product, Wengjing Decoction Granules, which is derived from a historical prescription and is aimed at treating specific gynecological conditions [1] Group 1: Product Information - Wengjing Decoction Granules is based on a prescription from the Song Dynasty and is included in the first batch of the National Administration of Traditional Chinese Medicine's list of classic ancient formulas [1] - The formulation consists of nine ingredients, including cinnamon, wine-soaked angelica, chuanxiong, vinegar-curcuma, peony root, and wine-soaked achyranthes [1] - The product is indicated for conditions such as menstrual irregularities and abdominal pain due to blood deficiency and stagnation [1] Group 2: Financial Investment - The company has invested a total of 10.7155 million RMB in the research and development of this product to date [1]

Meeting Overview - The fifth extraordinary general meeting of shareholders was held on October 10, 2025, at the company's conference room [2] - The meeting was conducted in accordance with the Company Law and the company's articles of association, combining on-site and online voting [2][3] Attendance and Voting - All 15 current directors and 5 supervisors attended the meeting, along with the board secretary [3] - The meeting's agenda included a non-cumulative voting proposal regarding the use of idle funds to purchase bank wealth management products, which was approved [3][4] Legal Verification - The meeting was witnessed by lawyers from Inner Mongolia Jianzhong Law Firm, who confirmed that the meeting's procedures complied with relevant laws and regulations [4] - The legal opinion stated that the qualifications of attendees were valid and the voting procedures and results were legitimate [4]

证券代码：600535 证券简称：天士力 编号：临2025-067号 天士力医药集团股份有限公司 2025年第五次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2025 年 10 月 10 日 (二) 股东大会召开的地点：天士力医药集团股份有限公司会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 1,457 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 659,271,256 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的比例（%） | 46.4520 | (四) 表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次会议采取现场投票与网络投票相结合的方式召开及表决。会议由公司董事 会召集，根据《公司章程》有关规定，由董事长周辉女士现场主持本次会议。会议 的召 ...

本所同意贵公司将本法律意见书作为贵公司本次股东大会公告材料，随其他 文件一同公开披露，并对贵公司引用的本法律意见承担相应的法律责任。 本所经办律师根据《证券法》、《股东大会规则》和《章程》的要求，按照 内蒙古建中律师事务所 关于天士力医药集团股份有限公司 2025 年第五次临时股东大会的法律意见书 2025 内建中券意字第 24 号 致：天士力医药集团股份有限公司 内蒙古建中律师事务所（以下称"本所"）受天士力医药集团股份有限公司 （以下称"贵公司"或"公司"）的委托，指派本所执业律师郭瑞鹏、张辛羽（以 下称"本所经办律师"）出席了贵公司 2025 年第五次临时股东大会（以下称"本 次股东大会"），并根据《中华人民共和国证券法》（以下称"《证券法》"）、 《中华人民共和国公司法》（以下称"《公司法》"）和中国证监会《上市公司 股东大会规则》（以下称"《股东大会规则》"）等法律、法规和规范性文件以 及《天士力医药集团股份有限公司章程》（以下称"《章程》"）的规定，就本 次股东大会的召集、召开程序、出席会议人员资格以及表决程序和表决结果的合 法有效性出具本法律意见书。 为出具本法律意见书，本所经办律师已对本次股东 ...

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. announced a cash dividend distribution of 0.21 CNY per share for the first half of 2025, approved at the fourth extraordinary general meeting of shareholders on September 2, 2025 [2][4]. Summary by Sections Dividend Distribution - The cash dividend distribution is set at 0.21 CNY per share, amounting to a total cash distribution of approximately 313.73 million CNY based on a total share capital of 1,493,950,005 shares [2][4]. Distribution Objects - The distribution will be made to all shareholders registered with the China Securities Depository and Clearing Corporation Limited Shanghai Branch as of the close of trading on the day before the equity registration date [3]. Implementation Method - For shareholders with unrestricted circulating shares, dividends will be distributed through the clearing system of the China Securities Depository and Clearing Corporation Limited. Shareholders who have completed designated transactions can collect their cash dividends at their designated securities business department on the dividend distribution date [5]. Special Distribution Cases - Certain entities, such as China Resources Sanjiu Medical & Pharmaceutical Co., Ltd., Tasly Biopharmaceutical Industry Group Co., Ltd., and Tianjin New Technology Industry Park Yongsheng Construction Co., Ltd., will receive their cash dividends directly from the company [6]. Taxation Details - For individual shareholders holding shares for over one year, the cash dividend of 0.21 CNY per share is exempt from individual income tax. For those holding shares for one year or less, the tax will be calculated upon the transfer of shares [9]. - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in a net cash dividend of 0.189 CNY per share [10]. - For Hong Kong investors, a similar 10% withholding tax applies, leading to a net cash dividend of 0.189 CNY per share [10]. - Other corporate shareholders will not have tax withheld by the company and must determine their tax obligations independently, receiving a cash dividend of 0.21 CNY per share [10].

Core Points - Tianjin Tasly Pharmaceutical announced its profit distribution plan for the first half of 2025, which includes a cash dividend of 0.21 yuan per share (tax included) for A-shares [2] - The record date for the dividend is set for October 16, 2025, while the ex-dividend date and the date of cash dividend distribution are both scheduled for October 17, 2025 [2]